http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Go, Dong Jin,Shin, Kichul,Baek, Han Joo,Kang, Seong Wook,Kang, Young Mo,Jun, Jae Bum,Lee, Yun Jong,Park, Sung Hwan,Song, Yeong Wook AMB ACTA MEDICA BELGICA 2018 CLINICAL RHEUMATOLOGY Vol.37 No.2
<P>The purpose of this study is to examine the patient-reported outcomes (PRO) after discontinuing nonsteroidal anti-inflammatory drugs (NSAIDs) and clinical factors associated with a favorable outcome in patients with rheumatoid arthritis (RA) in remission or with low-disease activity (LDA). A 16-week prospective open-label trial was conducted at eight rheumatology clinics in Korea. RA patients with 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) < 3.2 who were on NSAIDs for more than a month were enrolled, and NSAIDs were discontinued. Acetaminophen (AAP) was used as the rescue medication, and NSAIDs were restarted when joint pain was intolerable with AAP. The endpoint was to analyze the group of patients who continued to withdraw NSAIDs. Among 109 enrolled patients, 105 completed the 16-week follow-up. Eighty-nine (84.8%) patients remained without restarting NSAIDs. In these patients, there was a slight increase in their pain levels compared with baseline (median 14.0 versus 19.0 using the pain-visual analog scale, p = 0.010). However, changes in DAS28-ESR (p = 0.638) and routine assessment of patient index data 3 (RAPID-3) (p = 0.128) were insignificant. Moreover, 66 (62.9%) patients showed sustained effectiveness on PRO without restarting NSAIDs. In the multivariate regression models, joint swelling was the detrimental factor in NSAID withdrawal (odds ratio [OR] 0.149, 95% confidence interval [CI] 0.033-0.680, p = 0.014) and sustained effectiveness (OR 0.284, 95% CI 0.091-0.883, p = 0.030). Joint pain in RA patients in remission or with LDA can be well managed without NSAIDs, especially in those without swollen joints at the time of cessation.</P>
Park Jin Kyun,Lee Eun Bong,Shin Kichul,Sung Yoon-Kyoung,Kim Tae Hwan,Kwon Seong-Ryul,Lee Myeung Su,Hong Seung-Jae,Choi Byoong Yong,Lee Shin-Seok,Back Han Joo 대한의학회 2021 Journal of Korean medical science Vol.36 No.12
The coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who are immunocompromised due to underlying immune dysfunction and concomitant immunosuppressive treatment, warrants clear guidance. A task force of the Korean College of Rheumatology formulated a set of vaccination guidance based on the currently available data and expert consensus. The currently available COVID-19 vaccines are considered to be safe and effective. Every patient with AIIRD should receive one of the available COVID-19 vaccines unless contraindicated for medical reasons such as prior allergy/anaphylaxis to the COVID-19 vaccine or its components. Patients should continue immunosuppressive treatment for their underlying AIIRD, including biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Corticosteroids should be reduced to the lowest dose possible without aggravating the AIIRD. To improve the vaccine response, methotrexate can be withheld for 1–2 weeks after each vaccination, and the timing of rituximab and abatacept infusion should be adjusted if clinically acceptable. Rheumatologists should play a leading role in educating and vaccinating patients with AIIRD.
Conceptual Design of HTS Magnet for a 5 MJ Class SMES
Myungjin Park,Sangyeop Kwak,Wooseok Kim,Jikwang Lee,Jinho Han,Kyeongdal Choi,Hyunkyo Jung,Joonhan Bae,Seokho Kim,Kiduk Sim,Haejong Kim,Kichul Seong,Songyop Hanh IEEE 2008 IEEE transactions on applied superconductivity Vol.18 No.2
<P>Superconducting magnetic energy storage (SMES) systems with High Temperature Superconducting (HTS) wires have been actively developed world-wide. A 600 kJ class SMES with Bi-2223 HTS wire has been in development as a national project since 2004 and is currently approaching the final testing stage of the first of three phases. In the second phase of the project, several MJ class HTS SMES will be developed. In this paper, designs of magnets for 5 MJ class SMES with DI-BSSCO and YBCO coated conductor are presented and compared.</P>